The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | The TAUTEM study: transanal endoscopic microsurgery vs. total mesorectal excision
Patient quality of life is often at a detriment when using total mesorectal excision (TME) for the treatment of rectal adenocarcinom. Xavier Serra-Aracil, MD, PhD, Parc Tauli University Hospital, Barcelona, Spain, discusses preoperative, surgical and pathological outcomes from the TAUTEM study (NCT01308190), a prospective, multicenter, randomized controlled non-inferiority trial which aims to demonstrate the non-inferiority of the oncological outcomes and the improvement in morbidity and quality of life achieved with chemoradiotherapy and transanal endoscopic microsurgery (CRT-TEM) compared with TME. CRT-TEM treatment obtains high pathological complete response rates (45.3%), with a high CRT compliance rate (97.6%) and low morbidity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
